The therapeutic efficacy of the HELA-Exos was further evidenced by the fact that compared to breast tissues in the medium control and Hiltonol-treated groups, isolated breast cancer tissues exhibited the lowest Ki67 expression and the highest CASP3 and CRT expression (Fig. 4E). The gene discussed is CALR; the disease is breast carcinoma.